[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "(857) 209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 64, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 943020, "exercisedValue": 0, "unexercisedValue": 137562}, {"maxAge": 1, "name": "Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.", "age": 77, "title": "Founder & Independent Director", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 48125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 648600, "exercisedValue": 0, "unexercisedValue": 54705}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 58, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 721087, "exercisedValue": 0, "unexercisedValue": 86025}, {"maxAge": 1, "name": "Dr. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preetam  Shah M.B.A., Ph.D.", "age": 51, "title": "Chief Strategy & Financial Officer and Treasurer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thian  Kheoh Ph.D.", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.05, "open": 9.94, "dayLow": 9.178, "dayHigh": 9.94, "regularMarketPreviousClose": 10.05, "regularMarketOpen": 9.94, "regularMarketDayLow": 9.178, "regularMarketDayHigh": 9.94, "payoutRatio": 0.0, "beta": 2.122, "forwardPE": -3.6381326, "volume": 117582, "regularMarketVolume": 117582, "averageVolume": 93406, "averageVolume10days": 85480, "averageDailyVolume10Day": 85480, "bid": 9.13, "ask": 9.47, "bidSize": 1, "askSize": 1, "marketCap": 152762960, "fiftyTwoWeekLow": 4.05, "fiftyTwoWeekHigh": 12.62, "allTimeHigh": 263.0, "allTimeLow": 2.96, "fiftyDayAverage": 10.7835, "twoHundredDayAverage": 8.205675, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 145441808, "profitMargins": 0.0, "floatShares": 10640361, "sharesOutstanding": 16338284, "sharesShort": 609460, "sharesShortPriorMonth": 465308, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.0373, "heldPercentInsiders": 0.39359, "heldPercentInstitutions": 0.0968, "shortRatio": 8.8, "shortPercentOfFloat": 0.0571, "impliedSharesOutstanding": 16338284, "bookValue": 0.113, "priceToBook": 82.74337, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -54612000, "trailingEps": -3.98, "forwardEps": -2.57, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -3.277, "52WeekChange": 0.8927126, "SandP52WeekChange": 0.13837254, "quoteType": "EQUITY", "currentPrice": 9.35, "targetHighPrice": 18.0, "targetLowPrice": 13.0, "targetMeanPrice": 15.5, "targetMedianPrice": 15.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 22088000, "totalCashPerShare": 1.353, "ebitda": -44383000, "totalDebt": 14902000, "quickRatio": 2.226, "currentRatio": 2.277, "debtToEquity": 812.541, "returnOnAssets": -1.23261, "returnOnEquity": -600.1319, "freeCashflow": -20259500, "operatingCashflow": -35087000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ELTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Elicio Therapeutics, Inc.", "shortName": "Elicio Therapeutics, Inc.", "regularMarketChangePercent": -6.96517, "regularMarketPrice": 9.35, "corporateActions": [], "postMarketTime": 1760731804, "regularMarketTime": 1760731201, "exchange": "NCM", "messageBoardId": "finmb_214936128", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "epsTrailingTwelveMonths": -3.98, "epsForward": -2.57, "epsCurrentYear": -2.17, "priceEpsCurrentYear": -4.308756, "fiftyDayAverageChange": -1.4334993, "fiftyDayAverageChangePercent": -0.13293451, "twoHundredDayAverageChange": 1.1443253, "twoHundredDayAverageChangePercent": 0.13945535, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Angion Biomedica Corp.", "nameChangeDate": "2025-10-16", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612535400000, "postMarketChangePercent": 0.0, "postMarketPrice": 9.35, "postMarketChange": 0.0, "regularMarketChange": -0.7, "regularMarketDayRange": "9.178 - 9.94", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 93406, "fiftyTwoWeekLowChange": 5.3, "fiftyTwoWeekLowChangePercent": 1.3086419, "fiftyTwoWeekRange": "4.05 - 12.62", "fiftyTwoWeekHighChange": -3.2699995, "fiftyTwoWeekHighChangePercent": -0.25911248, "fiftyTwoWeekChangePercent": 89.271255, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "displayName": "Elicio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-18"}]